Bladder and bowel dysfunction in Parkinson's disease

被引:144
作者
Sakakibara, R. [1 ,2 ]
Uchiyama, T. [2 ]
Yamanishi, T. [3 ]
Shirai, K. [1 ]
Hattori, T. [2 ]
机构
[1] Toho Univ, Div Neurol, Sakura Med Ctr, Dept Internal Med, 564-1 Shimoshizu, Sakura, Ibaraki 2858741, Japan
[2] Chiba Univ, Dept Neurol, Chiba, Japan
[3] Dokkyo Med Coll, Dept Urol, Mibu, Tochigi, Japan
关键词
Parkinson's disease; bladder dysfunction; bowel dysfunction; autonomic nervous system; dopamine;
D O I
10.1007/s00702-007-0855-9
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Bladder dysfunction (urinary urgency/frequency) and bowel dysfunction (constipation) are common non-motor disorders in Parkinson's disease (PD). In contrast to motor disorder, the pelvic autonomic dysfunction is often non-responsive to levodopa treatment. Brain pathology mostly accounts for the bladder dysfunction (appearance of overactivity) via altered dopamine-basal ganglia circuit, which normally suppresses the micturition reflex. In contrast, peripheral enteric pathology mostly accounts for the bowel dysfunction (slow transit and decreased phasic contraction) via altered dopamine-enteric nervous system circuit, which normally promotes the peristaltic reflex. In addition, weak strain and paradoxical anal contraction might be the results of brain pathology. Pathophysiology of the pelvic organ dysfunction in PD differs from that in multiple system atrophy; therefore it might aid the differential diagnosis. Drugs to treat bladder dysfunction in PD include anticholinergic agents. Drugs to treat bowel dysfunction in PD include dietary fibers, peripheral dopaminergic antagonists, and selective serotonergic agonists. These treatments might be beneficial not only in maximizing patients' quality of life, but also in promoting intestinal absorption of levodopa and avoiding gastrointestinal emergency.
引用
收藏
页码:443 / 460
页数:18
相关论文
共 208 条
[161]  
Seki S, 2001, NEUROUROL URODYNAM, V20, P105, DOI 10.1002/1520-6777(2001)20:1<105::AID-NAU12>3.0.CO
[162]  
2-9
[163]   AGGRAVATION OF PARKINSONIAN TREMOR BY CISAPRIDE [J].
SEMPERE, AP ;
DUARTE, J ;
CABEZAS, C ;
CLAVERIA, LE ;
CORIA, F .
CLINICAL NEUROPHARMACOLOGY, 1995, 18 (01) :76-78
[164]   Intestinal pseudo-obstruction and neuroleptic malignant syndrome in a chronically constipated parkinsonian patient [J].
Shimada, J ;
Sakakibara, R ;
Uchiyama, T ;
Liu, Z ;
Yamamoto, T ;
Ito, T ;
Mori, M ;
Asahina, M ;
Hattori, T .
EUROPEAN JOURNAL OF NEUROLOGY, 2006, 13 (03) :306-307
[165]   DOMPERIDONE AND LEVODOPA IN PARKINSONS-DISEASE [J].
SHINDLER, JS ;
FINNERTY, GT ;
TOWLSON, K ;
DOLAN, AL ;
DAVIES, CL ;
PARKES, JD .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 18 (06) :959-962
[166]   Autonomic dysfunction in Parkinson's disease: a comprehensive symptom survey [J].
Siddiqui, MF ;
Rast, S ;
Lynn, MJ ;
Auchus, AP ;
Pfeiffer, RF .
PARKINSONISM & RELATED DISORDERS, 2002, 8 (04) :277-284
[167]   DOPAMINERGIC DEFECT OF ENTERIC NERVOUS-SYSTEM IN PARKINSONS-DISEASE PATIENTS WITH CHRONIC CONSTIPATION [J].
SINGARAM, C ;
ASHRAF, W ;
GAUMNITZ, EA ;
TORBEY, C ;
SENGUPTA, A ;
PFEIFFER, R ;
QUIGLEY, EMM .
LANCET, 1995, 346 (8979) :861-864
[168]   AUTONOMIC DYSFUNCTION IN MEN WITH PARKINSONS-DISEASE [J].
SINGER, C ;
WEINER, WJ ;
SANCHEZRAMOS, JR .
EUROPEAN NEUROLOGY, 1992, 32 (03) :134-140
[169]  
Smith Y, 1998, NEUROSCIENCE, V86, P353
[170]   Effect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson's disease [J].
Soykan, I ;
Sarosiek, I ;
Shifflett, J ;
Wooten, GF ;
McCallum, RW .
MOVEMENT DISORDERS, 1997, 12 (06) :952-957